Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319670 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children
A Phase 4 study, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT00319670 is a Phase 4 study that has completed, run by Braintree Laboratories. The registered enrollment target is 25 participants.
The verdict
NCT00319670, a Phase 4 study, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
To evaluate patient acceptance of a new MiraLax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.
Interventions
- DRUG MiraLax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319670
The ClinicalTrials.gov registry entry for NCT00319670 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MiraLax is the first listed.
NCT00319670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00319670 about?
NCT00319670 is a clinical study titled "A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children". To evaluate patient acceptance of a new MiraLax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.
What is the current status of trial NCT00319670?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2006-03.
What interventions are being tested in trial NCT00319670?
The interventions under investigation include: MiraLax (DRUG).
Who is sponsoring clinical trial NCT00319670?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.